Upstate to Offer Anti-ZAP-70 Monoclonal Antibody for Diagnostic Use

Serologicals announced that Upstate Group, its wholly owned subsidiary, obtained the rights from the University of California to sell the anti-ZAP-70 monoclonal antibody for diagnostic use. Studies show that the levels of expression of the ZAP-70 protein strongly predict the aggressiveness of chronic lymphocytic leukemia.

Business Wire (http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050328005461&newsLang=en)